Response to “Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients”
Marijke Linschoten, Linda Nab, Iwan C.C. van der Horst, Robert G Tieleman, Folkert W. Asselbergs
Abstract
With great interest, we read the observational study by Lammers et al., in which hydroxychloroquine (HCQ) was associated with a 53% risk reduction of transfer to the ICU in patients hospitalised with COVID-19 (Lammers et al., 2020). Given the limited number of effective drugs available, these results are of utmost interest. We think additional requirements need to be met before drawing the conclusion that HCQ is beneficial.
Topics & Concepts
HydroxychloroquineMedicineScopusCoronavirus disease 2019 (COVID-19)Intensive care unitObservational studyPandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ChloroquinePopulationInternal medicineIntensive carePediatricsEmergency medicineMEDLINEIntensive care medicineDiseasePathologyLawInfectious disease (medical specialty)Political scienceMalariaEnvironmental healthCOVID-19 Clinical Research StudiesSepsis Diagnosis and TreatmentLong-Term Effects of COVID-19